InMed Pharmaceuticals Inc.
INMNASDAQHealthcare● Active
$1.54
$-0.04(-2.53%)
Market Cap$2787286
P/E Ratio—
52W High$5.5
52W Low$0.575
InMed Pharmaceuticals Inc. (INM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · INM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $4.94M | $4.60M | $4.14M | $1.09M | $0.00M |
| Cost of Revenue | $3.24M | $3.50M | $2.73M | $0.55M | $0.00M |
| Gross Profit | $1.71M | $1.10M | $1.40M | $0.54M | $0.00M |
| Gross Margin %(computed) | 34.53% | 23.94% | 33.93% | 49.89% | — |
| Operating Expenses | |||||
| R&D Expenses | $2.85M | $3.22M | $3.73M | $7.28M | $6.62M |
| G&A Expenses | $6.56M | $5.80M | $5.85M | $6.87M | $5.55M |
| Total Operating Expenses | $9.62M | $9.24M | $9.78M | $14.34M | $12.17M |
| Operating Income | ($7.92M) | ($8.13M) | ($8.38M) | ($13.79M) | ($12.17M) |
| Operating Margin %(computed) | -160.20% | -176.92% | -202.60% | — | — |
| Interest Income | $0.16M | $0.72M | $0.65M | $0.12M | $0.02M |
| Interest Expense | $0.37M | $0.00M | $0.00M | $0.00M | $0.36M |
| Income Before Tax | ($8.16M) | ($7.67M) | ($7.93M) | ($18.60M) | ($12.65M) |
| Income Tax Expense | $0.00M | $0.01M | $0.01M | $0.00M | $0.00M |
| Net Income | ($8.16M) | ($7.68M) | ($7.95M) | ($18.60M) | ($12.65M) |
| Net Margin %(computed) | -165.14% | -166.94% | -192.18% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-8.36 | $-20.14 | $-64.92 | $-16582.00 | $-938.91 |
| Wtd Avg Shares | 0.98M | 0.38M | 0.12M | 0.00M | 0.01M |
| EBITDA | ($7.26M) | ($7.06M) | ($7.78M) | ($13.28M) | ($12.17M) |
| EBITDA Margin %(computed) | -146.80% | -153.64% | -188.19% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more InMed Pharmaceuticals Inc. data
About InMed Pharmaceuticals Inc. (INM) Income Statement
InMed Pharmaceuticals Inc. (INM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, INM reported revenue of $0.00B, gross profit of $0.00B (gross margin 34.53%), and net income of ($0.01B) — a net profit margin of -165.14%.
Frequently asked questions
INM · 4 questionsInMed Pharmaceuticals Inc. (INM) reported revenue of $0.00B for 2025, up 7.5% year-over-year.
INM revenueINM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08